A Single Ascending Dose Clinical Trial to Find the Maximum Tolerable Dose of HL237 in Healthy Male Subject

NCT03278470 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

57

Enrollment

INDUSTRY

Sponsor class

Conditions

Rheumatoid Arthritis

Interventions

DRUG: HL237
DRUG: Placebo Oral Tablet

Sponsor

Hanlim Pharm. Co., Ltd.